EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemotherapy may cause memory loss, attention loss, and other problems that make
it difficult for patients to think clearly. EGb761 may help maintain mental clarity in
patients undergoing chemotherapy.
PURPOSE: Randomized clinical trial to study the effectiveness of EGb761 in preventing loss of
mental clarity in women who are receiving chemotherapy for newly diagnosed breast cancer.